Skip to main content
GMAB logo

Genmab A/S (GMAB) Stock: Price, Forecast & Analyst Target

Genmab A/S (GMAB) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $50.97 (-1.91%), as of the Nov 18, 2026 trading session; market cap $31.4B.

Educational signal · not a buy or sell recommendation · How to read this

$50.97 −$0.99 (-1.91%) Market Cap $31.4B

Genmab A/S · GMAB · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: Genmab develops antibody medicines through a portfolio that already includes commercialized cancer and serious-disease therapies, partnered clinical programs, and proprietary development platforms. Its latest revenue and profit rebound now has to prove durable while the balance sheet carries substantially more debt than cash.

Price as of Nov 18, 2026

Key Statistics

72 of 100

MoonshotScore v2 · Genmab A/S (GMAB)

Strong
Business Quality Elite (90)
Financial Safety Okay (54)
Valuation Full (42)
Growth Durability Shrinking (5)
Momentum Surging (98)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.

  • EPS beat 6 of the last 8 reports
  • Altman Z 21.04 · Piotroski F 5
  • ROE 12.3% · ROA 5.6% · current ratio 2.45 · earnings yield 2.3% · free-cash-flow yield 2.6%

Holding back: soft growth

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GMAB (52 recorded, newest six shown)
RecordedScoreBand
69Strong
69Strong
68Strong
68Strong
72Strong
72Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$50.97
Change on the day-1.91%
52-week range$23.62–$59.97
Market capitalisation$31.4B—
Price / earnings (trailing)43.33
Shares traded on the day2.96M
Beta (volatility vs the S&P 500)0.65

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $25, high $57, latest $51. $57 $25 high $57 Oct 17, 2025 Nov 18, 2026 · $51 $33Oct 17, 2025$29Oct 31, 2025$30Nov 14, 2025$32Nov 28, 2025$31Dec 12, 2025$33Dec 26, 2025$34Jan 9, 2026$34Jan 23, 2026$31Feb 6, 2026$29Feb 20, 2026$27Mar 6, 2026$25Mar 20, 2026$28Apr 2, 2026$29Apr 17, 2026$26May 1, 2026$27May 15, 2026$26May 29, 2026$25Jun 12, 2026$26Jun 26, 2026$29Jul 10, 2026$29Jul 24, 2026$31Aug 7, 2026$33Aug 21, 2026$34Sep 4, 2026$35Sep 18, 2026$35Oct 2, 2026$37Oct 16, 2026$57Oct 30, 2026$51Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Genmab A/S (GMAB): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Negative
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Negative
Debt/Equity Weak
ROE Moderate
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Genmab A/S (GMAB), and what does it report?

Short answer · as of

Genmab discovers and develops antibody therapies.

Darzalex, teprotumumab, ofatumumab, amivantamab, and tisotumab vedotin sit in its commercialized portfolio, while epcoritamab and other candidates extend the business through collaborations and clinical development.

The reported revenue, gross profit, operating profit, and research spending are company-level outcomes from this blended model. Genmab is therefore not merely a biotechnology pipeline awaiting commercialization: marketed medicines and extensive research activity coexist inside the same business.

2 · Latest results

What do the latest results show for Genmab A/S (GMAB)?

Revenue rebounded in the latest reported period, while gross profit, operating profit, net income, and diluted earnings all improved from the preceding period. Research and administrative spending also rose, but the additional gross profit more than absorbed those increases.

Reported earnings and revenue exceeded expectations after consecutive disappointments. Management has set a full-year revenue range; that guidance describes the intended destination, while the latest results provide the first evidence of renewed operating momentum.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$1.02B$401M$0.65 (diluted)
Q4 FY2025$1.06B$31M—
Q1 FY2026$896M$53M$0.08 (diluted)
Q2 FY2026$1.16B$303M$0.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Genmab A/S (GMAB)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Genmab remains profitable, and every period in the available cash-flow series produced positive operating cash flow. Annual results also show that substantial research investment has coexisted with net income, while liquidity ratios and the distress screen do not indicate immediate pressure from current obligations.

The harder balance-sheet issue is the gap between cash and debt. Cash and investments have fallen sharply across the reported window, operating cash generation has been uneven, and debt now exceeds available cash by a wide margin. That combination makes the direction of cash as important as reported operating profit.

4 · What to check next?

What should you watch next at Genmab A/S (GMAB)?

Short answer · as of

Current published price targets run low $40.00 · high $70.00 · consensus $50.83 · median $47.50 against a quoted price of $50.97 (as of Nov 18, 2026).

Watch whether revenue sustains its latest rebound, whether operating profit keeps expanding despite higher research and administrative spending, and whether operating cash flow strengthens from subdued recent levels. Stabilization in cash relative to debt would make the accounting recovery more convincing.

The scheduled earnings release will also test progress toward management’s full-year revenue range. Longer-horizon analyst estimates anticipate continued revenue growth but span increasingly varied outcomes, placing commercial execution and pipeline conversion at the center of what follows.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Genmab A/S compare with its peers?

Short answer

Genmab A/S's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Genmab combines marketed antibody medicines, proprietary antibody formats, partnered programs, and a sizable internal organization. That is a different operating shape from a research-stage antibody developer whose value depends mainly on clinical candidates.

It also differs from a conventional commercial drugmaker because research remains a major expense and collaborations with AbbVie, Seagen, CureVac, BioNTech, Janssen, and Novo Nordisk extend development across counterparties. The resulting business has several routes to value creation, but its outcomes depend on partner execution and clinical progress as well as demand for commercialized medicines.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Named competitor$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Genmab A/S (GMAB) — this page$50.97$31.4B72

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$40.00 – $70.00
Consensus target
$50.83
Median target
$47.50

Consensus record · Captured .

Measured against a quoted price of $50.97 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GMAB in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GMAB in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Genmab A/S (GMAB)?

Read these with our analysis →

What Investors Ask About Genmab A/S (GMAB) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Darzalex important to Genmab?

Darzalex is a commercialized human monoclonal antibody used in multiple myeloma, other blood cancers, and amyloidosis. Its presence helps make Genmab an operating medicines business rather than solely a collection of experimental programs.

How does AbbVie fit into Genmab’s epcoritamab program?

AbbVie is Genmab’s development partner for epcoritamab, which is being pursued in relapsed or refractory lymphoma and chronic lymphocytic leukemia. The arrangement places a prominent pipeline asset inside a collaborative development model.

Why do DuoBody and HexaBody matter to Genmab?

DuoBody and HexaBody candidates appear across solid-tumor and hematologic programs. Their use throughout the pipeline shows how Genmab applies its antibody-development formats across distinct disease targets rather than tying research to a lone medicine.

Why can Genmab’s cash balance fall while operations generate cash?

Operating cash flow remained positive across the reported periods, yet cash and short-term investments declined sharply. Operating cash flow captures only part of total cash movement, so the balance can fall even when the core cash-flow measure stays positive.

What is the GMAB stock price today?

The last price recorded for Genmab A/S (GMAB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GMAB price target?

The analyst consensus price target for Genmab A/S (GMAB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Ticker / exchange; Business description; Quarterly income statement (USD thousands); Cash, investments and debt
  • 1. What is Genmab A/S (GMAB), and what does it report?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Genmab A/S (GMAB)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Genmab A/S (GMAB)?: Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Genmab A/S (GMAB)?: Next earnings report; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Analyst revenue and earnings estimates (average)
  • 5. How does Genmab A/S compare with its peers?: Business description; Employees; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Why is Darzalex important to Genmab?: Business description
  • FAQ: How does AbbVie fit into Genmab’s epcoritamab program?: Business description
  • FAQ: Why do DuoBody and HexaBody matter to Genmab?: Business description
  • FAQ: Why can Genmab’s cash balance fall while operations generate cash?: Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash and investment components
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.